Margo Roberts
Director/Board Member chez UNITY BIOTECHNOLOGY, INC.
Fortune : - $ au 31/03/2024
Profil
Margo R.
Roberts is an Independent Director at Unity Biotechnology, Inc. and a Director at Appia Bio, Inc. She was previously a Director-Immune & Cell Therapy at Cell Genesys, Inc. and an Associate Professor at the University of Virginia.
She was also the Chief Scientific Officer & SVP-Discovery Research at Kite Pharma, Inc. and the Chief Scientific Officer at Lyell Immunopharma, Inc. Additionally, she served as an Independent Director at Celyad Oncology SA. She holds undergraduate and doctorate degrees from the University of Leeds.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 23/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Margo Roberts
| Sociétés | Poste | Début |
|---|---|---|
| UNITY BIOTECHNOLOGY, INC. | Director/Board Member | 04/12/2018 |
Appia Bio, Inc.
 Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Director/Board Member | 09/08/2022 |
Anciens postes connus de Margo Roberts
| Sociétés | Poste | Fin |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 01/01/2021 |
| CELYAD ONCOLOGY SA | Director/Board Member | 06/08/2020 |
| KITE PHARMA INC | Chief Tech/Sci/R&D Officer | 01/07/2018 |
| University of Virginia | Corporate Officer/Principal | 01/12/2011 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Corporate Officer/Principal | 01/12/1998 |
Formation de Margo Roberts
| University of Leeds | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| CELYAD ONCOLOGY SA | Health Technology |
| UNITY BIOTECHNOLOGY, INC. | Health Technology |
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| INSTIL BIO, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Health Technology |
